Omnicell (OMCL) Stock Price, News & Analysis

Company Overview

Omnicell, Inc. is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum. The company completed its initial public offering on the Nasdaq under the ticker OMCL and has invested heavily in research and development, focusing on robotics, bar-coding and cloud-based data services. Omnicell’s continuous product enhancements reflect its commitment to automating complex pharmacy processes and driving digital transformation in healthcare.

Omnicell serves a global customer base that includes acute care hospitals, health systems, retail pharmacies and long-term care facilities. While its primary market remains North America, the company maintains operations and support centers throughout Europe and the Asia-Pacific region. This international footprint enables Omnicell to tailor solutions to diverse regulatory environments and to partner with healthcare organizations worldwide in improving medication safety and operational efficiency.

Under the leadership of co-founder and Chief Executive Officer Randall A. Lipps, Omnicell has expanded its technology suite to address emerging needs such as antimicrobial stewardship, telepharmacy and remote drug distribution. The company’s executive team continues to prioritize innovation, seeking to integrate advanced analytics and artificial intelligence into its platforms to help clinicians make more informed decisions and enhance overall patient care.

Key Stats

• Today's Range: $43.04 to $44.15
• 50-Day Range: $32.35 to $45.51
• 52-Week Range: $24.23 to $55.00
• Volume: 40,146 shs
• Average Volume: 634,778 shs
• Market Capitalization: $1.98 billion
• P/E Ratio: 98.67
• Dividend Yield: N/A
• Price Target: $59.86
• Consensus Rating: Moderate Buy

Omnicell Stock Analysis - MarketRank™

Omnicell scored higher than 62% of companies evaluated by MarketBeat, and ranked 302nd out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Omnicell has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 1 strong buy rating, 7 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Omnicell has a consensus price target of $59.86, representing about 38.2% upside from its current price of $43.32.

Amount of Analyst Coverage

Omnicell has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: 0.75%

Earnings Growth

Earnings for Omnicell are expected to grow by 0.75% in the coming year, from $1.34 to $1.35 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Omnicell is 98.45, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.28.

Price to Earnings Ratio vs. Sector

The P/E ratio of Omnicell is 98.45, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 29.02.

Price to Earnings Growth Ratio

Omnicell has a PEG Ratio of 1.09. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Omnicell has a P/B Ratio of 1.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.69% of the float of Omnicell has been sold short.

Short Interest Ratio / Days to Cover

Omnicell has a short interest ratio ("days to cover") of 7.7.

Change versus previous month

Short interest in Omnicell has recently increased by 0.74%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Omnicell does not currently pay a dividend.

Dividend Growth

Omnicell does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.65

News Sentiment

Omnicell has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Omnicell this week, compared to 4 articles on an average week.

MarketBeat Follows

8 people have added Omnicell to their MarketBeat watchlist in the last 30 days. This is an increase of 700% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Omnicell insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $256,879.00 in company stock.

Percentage Held by Insiders

2.92% of the stock of Omnicell is held by insiders.

Percentage Held by Institutions

97.70% of the stock of Omnicell is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

OMCL Stock Analysis - Frequently Asked Questions

How have OMCL shares performed this year?

Omnicell's stock was trading at $45.30 at the start of the year. Since then, OMCL shares have decreased by 4.4% and is now trading at $43.3160.

How were Omnicell's earnings last quarter?

Omnicell, Inc. (NASDAQ:OMCL) posted its earnings results on Tuesday, April, 28th. The company reported $0.55 earnings per share for the quarter, topping the consensus estimate of $0.33 by $0.22. The firm's revenue was up 14.9% on a year-over-year basis.
Read the conference call transcript.

Does Omnicell have any subsidiaries?

The following companies are subsidiaries of Omnicell: MarkeTouch Media LLC, ReCept Pharmacy, FDS Amplicare, 340B Link Business, InPharmics, Ateb Inc., Aesynt, and others.

Who are Omnicell's major shareholders?

Omnicell's top institutional investors include Sumitomo Mitsui Trust Group Inc. (3.10%), Bank of New York Mellon Corp (0.95%), Principal Financial Group Inc. (0.65%) and Burney Co. (0.47%). Insiders that own company stock include Randall A Lipps, Corey J Manley, Mark W Parrish and Christine Marie Mellon.
View institutional ownership trends.

How do I buy shares of Omnicell?

Shares of OMCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Omnicell own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Omnicell investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Broadcom (AVGO) and Palo Alto Networks (PANW).

Company Calendar

• Last Earnings: 4/28/2026
• Today: 5/06/2026
• Bank of America Global Healthcare Conference 2026: 5/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MEDICAL INFO SYS
• Sub-Industry: Health Care Technology
• Current Symbol: NASDAQ:OMCL
• CIK: 926326
• Web: www.omnicell.com
• Phone: (877) 415-9990
• Fax: 847-596-3402
• Employees: 3,580
• Year Founded: 1992

Price Target and Rating

• Average Price Target for Omnicell: $59.86
• High Price Target: $70.00
• Low Price Target: $49.00
• Potential Upside/Downside: +37.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.89
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.44
• Trailing P/E Ratio: 98.67
• Forward P/E Ratio: 32.43
• P/E Growth: 1.09
• Net Income: $2.05 million
• Net Margins: 1.67%
• Pretax Margin: 3.08%
• Return on Equity: 4.00%
• Return on Assets: 2.46%

Debt

• Debt-to-Equity Ratio: 0.13
• Current Ratio: 1.50
• Quick Ratio: 1.29

Sales & Book Value

• Annual Sales: $1.18 billion
• Price / Sales: 1.67
• Cash Flow: $2.77 per share
• Price / Cash Flow: 15.71
• Book Value: $27.63 per share
• Price / Book: 1.57

Miscellaneous

• Outstanding Shares: 45,480,000
• Free Float: 44,149,000
• Market Cap: $1.98 billion
• Optionable: Optionable
• Beta: 0.96